ENYO Pharma

ENYO Pharma is a biotechnology company developing therapeutics for diseases with impaired kidney function. Their lead candidate, Vonafexor, is a highly selective FXR agonist with anti-inflammatory and fibrolytic properties, currently in a Phase 2 clinical trial for Alport Syndrome. The company also has a fast-follower compound, EYP651, with similar properties.

Funding Round: Series C

Funding Amount: €39M

Date: 03-Jan-2024

Investors: OrbiMed, Morningside Ventures, AndEra Partners, Bpifrance InnoBio, Bpifrance Large Ventures

Markets: Biotechnology, Pharmaceuticals, Renal Diseases, Biopharma, Medical

HQ: Lyon, Auvergne-Rhône-Alpes, France

Founded: 2014

Website: https://www.enyopharma.com/

LinkedIn: https://www.linkedin.com/company/enyo-pharma/

Twitter: https://twitter.com/enyopharma

Instagram:

Facebook: